Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01435122 · OUTCOME

Median Progression Free Survival

A Study of Axitinib in Advanced Carcinoid Tumors · Source last updated 2018-10-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 36 Months

What was measured

Post follow-up progression free survival at time of analysis.

Analysis population: All participants.

Groups in this outcome

Axitinib Administration

The investigational drug used in this study is axitinib, and is available as tablets.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Axitinib Administration30

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Axitinib Administration26.7Not reported11.435.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        11.4
        upper Limit
        35.1
        value
        26.7
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
Post follow-up progression free survival at time of analysis.
dispersion Type
95% Confidence Interval
groups
  1. description
    The investigational drug used in this study is axitinib, and is available as tablets.
    id
    OG000
    title
    Axitinib Administration
param Type
MEDIAN
population Description
All participants.
reporting Status
POSTED
time Frame
Up to 36 Months
title
Median Progression Free Survival
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice